Maciocia, Nicola;
Wade, Brandon;
Maciocia, Paul;
(2025)
CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure?
Blood Advances
, 9
(4)
pp. 913-923.
10.1182/bloodadvances.2023012263.
Preview |
Text
main.pdf - Published Version Download (1MB) | Preview |
Abstract
Chimeric antigen receptor T-cell (CAR-T) therapy has proven successful for B-cell lymphomas and leukemias. This success has inspired the development of CAR-T for T-cell malignancies. T-cell lymphomas and T-cell acute lymphoblastic leukemia (T-ALL) are highly heterogenous diseases but are united by poor prognosis in the relapsed/refractory setting and the lack of any novel, targeted therapies. CAR-T therapy is a promising solution for these diseases but carries a number of challenges, principally that target antigens are typically shared between malignant and normal T cells. This can cause issues with fratricide and T-cell aplasia. In this review we discuss the current state of CAR-T treatment for T-ALL and T-cell lymphomas, highlighting recent novel clinical data for T-cell malignancies and discuss lessons that can be learned for future research in this area.
| Type: | Article |
|---|---|
| Title: | CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure? |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1182/bloodadvances.2023012263 |
| Publisher version: | https://doi.org/10.1182/bloodadvances.2023012263 |
| Language: | English |
| Additional information: | © 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. |
| Keywords: | Humans, Immunotherapy, Adoptive, Receptors, Chimeric Antigen, T-Lymphocytes, Receptors, Antigen, T-Cell, Treatment Outcome, Lymphoma, T-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10206061 |
Loading...
Loading...Loading...Loading...Archive Staff Only
 |
View Item |
